Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis
- PMID: 23917901
- DOI: 10.1086/672271
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis
Erratum in
- Infect Control Hosp Epidemiol. 2013 Nov;34(11):1238. Dosage error in article text
Abstract
This report updates US Public Health Service recommendations for the management of healthcare personnel (HCP) who experience occupational exposure to blood and/or other body fluids that might contain human immunodeficiency virus (HIV). Although the principles of exposure management remain unchanged, recommended HIV postexposure prophylaxis (PEP) regimens and the duration of HIV follow-up testing for exposed personnel have been updated. This report emphasizes the importance of primary prevention strategies, the prompt reporting and management of occupational exposures, adherence to recommended HIV PEP regimens when indicated for an exposure, expert consultation in management of exposures, follow-up of exposed HCP to improve adherence to PEP, and careful monitoring for adverse events related to treatment, as well as for virologic, immunologic, and serologic signs of infection. To ensure timely postexposure management and administration of HIV PEP, clinicians should consider occupational exposures as urgent medical concerns, and institutions should take steps to ensure that staff are aware of both the importance of and the institutional mechanisms available for reporting and seeking care for such exposures. The following is a summary of recommendations: (1) PEP is recommended when occupational exposures to HIV occur; (2) the HIV status of the exposure source patient should be determined, if possible, to guide need for HIV PEP; (3) PEP medication regimens should be started as soon as possible after occupational exposure to HIV, and they should be continued for a 4-week duration; (4) new recommendation-PEP medication regimens should contain 3 (or more) antiretroviral drugs (listed in Appendix A ) for all occupational exposures to HIV; (5) expert consultation is recommended for any occupational exposures to HIV and at a minimum for situations described in Box 1 ; (6) close follow-up for exposed personnel ( Box 2 ) should be provided that includes counseling, baseline and follow-up HIV testing, and monitoring for drug toxicity; follow-up appointments should begin within 72 hours of an HIV exposure; and (7) new recommendation-if a newer fourth-generation combination HIV p24 antigen-HIV antibody test is utilized for follow-up HIV testing of exposed HCP, HIV testing may be concluded 4 months after exposure ( Box 2 ); if a newer testing platform is not available, follow-up HIV testing is typically concluded 6 months after an HIV exposure.
Comment in
-
Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting.Infect Control Hosp Epidemiol. 2014 Mar;35(3):326-8. doi: 10.1086/675297. Infect Control Hosp Epidemiol. 2014. PMID: 24521604 No abstract available.
-
Reply to Tan et al.Infect Control Hosp Epidemiol. 2014 Mar;35(3):328-9. doi: 10.1086/675350. Infect Control Hosp Epidemiol. 2014. PMID: 24521605 Free PMC article. No abstract available.
Similar articles
-
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.MMWR Recomm Rep. 2001 Jun 29;50(RR-11):1-52. MMWR Recomm Rep. 2001. PMID: 11442229
-
Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis.MMWR Recomm Rep. 2005 Sep 30;54(RR-9):1-17. MMWR Recomm Rep. 2005. PMID: 16195697
-
Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. Centers for Disease Control and Prevention.MMWR Recomm Rep. 1998 May 15;47(RR-7):1-33. MMWR Recomm Rep. 1998. PMID: 9603630
-
Postexposure prophylaxis against human immunodeficiency virus.Am Fam Physician. 2010 Jul 15;82(2):161-6. Am Fam Physician. 2010. PMID: 20642270 Review.
-
[Post-exposure HIV prevention within and outside the hospital].Ther Umsch. 1998 May;55(5):289-94. Ther Umsch. 1998. PMID: 9643126 Review. German.
Cited by
-
Incidence and Risks of HIV Infection, Medication Options, and Adverse Effects in Accidental Needle Stick Injuries: A Narrative Review.Cureus. 2024 Jan 2;16(1):e51521. doi: 10.7759/cureus.51521. eCollection 2024 Jan. Cureus. 2024. PMID: 38304675 Free PMC article. Review.
-
Adherence, adverse drug reactions, and discontinuation associated with adverse drug reactions of HIV post-exposure prophylaxis: a meta-analysis based on cohort studies.Ann Med. 2023;55(2):2288309. doi: 10.1080/07853890.2023.2288309. Epub 2023 Dec 8. Ann Med. 2023. PMID: 38065681 Free PMC article.
-
Southern African HIV Clinicians Society 2023 Guideline for post-exposure prophylaxis: Updated recommendations.South Afr J HIV Med. 2023 Sep 28;24(1):1522. doi: 10.4102/sajhivmed.v24i1.1522. eCollection 2023. South Afr J HIV Med. 2023. PMID: 37795431 Free PMC article. No abstract available.
-
Peripartum management of HIV-positive patients.BJA Educ. 2023 Oct;23(10):382-388. doi: 10.1016/j.bjae.2023.05.008. Epub 2023 Aug 8. BJA Educ. 2023. PMID: 37720556 Review. No abstract available.
-
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.BMC Infect Dis. 2023 Sep 4;23(1):578. doi: 10.1186/s12879-023-08544-x. BMC Infect Dis. 2023. PMID: 37667182 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous